38
Grade D

Patient Fusion Privacy Policy

Practice Fusion Portal (Veradigm) | Last reviewed: January 2026

DOJ Settlement: Practice Fusion paid $145 million in 2020 after the DOJ found it accepted kickbacks from opioid manufacturers to implement clinical decision support that encouraged opioid prescriptions. This demonstrates how data monetization pressures can compromise patient interests.

Privacy Summary

Practice Fusion pioneered the "free EHR" model sustained by data monetization. Patient Fusion users should understand their health data has historically been a revenue source through pharmaceutical advertising, research data sales, and analytics products. The DOJ settlement addressed some practices, but the underlying business model remains data-dependent.

Data Collection Overview

Data Type Collected Shared Sold
Medical Records Yes Veradigm Network De-identified to pharma
Prescription Data Yes Data Aggregators Yes (historically)
Diagnoses Yes Research Partners De-identified
Clinical Decisions Yes Analytics Products Used for advertising targeting
Provider Interactions Yes Quality Metrics No

Key Privacy Concerns

Free Model = Data Product

When providers pay nothing for EHR software, patient data becomes the revenue source. Practice Fusion has sold de-identified data to pharmaceutical companies, researchers, and advertisers.

Pharmaceutical Industry Access

The DOJ settlement revealed that pharmaceutical companies paid Practice Fusion to influence prescribing through clinical alerts. While this specific practice stopped, pharma data relationships continue.

Veradigm Data Ecosystem

Practice Fusion is now part of Veradigm (formerly Allscripts), which operates extensive health data businesses. Your data may flow through multiple Veradigm products and partners.

Limited Transparency

The full scope of data partnerships and monetization is not clearly disclosed to patients. You may not know how your de-identified data is being used commercially.

The Data Monetization Model

How free EHR generates revenue from your data:

  • De-identified patient data sold to researchers
  • Pharmaceutical companies purchase prescribing analytics
  • Targeted clinical decision support (restricted post-settlement)
  • Aggregate data for market research
  • Analytics products sold to healthcare organizations